Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Novotny, Joe ^c   Singh, Amandeep ^c   Dysoley, Lek ^d,e   Sovannaroth, Siv ^d   Rekol, Huy ^d  

^a POPULATION SERVICES INTERNATIONAL   (United States)

^b PSI Cambodia (PSK)   (Cambodia)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

^d National Centre of Entomology Parasitological and Malaria Control   (Cambodia)

^e National Institute of Public Health   (Cambodia)

Author keywords

Anti malarial; Availability; Elimination; Market share; Outlet; Private sector; Public; Supply; Treatment

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ PIPERAQUINE; MEFLOQUINE; UNCLASSIFIED DRUG;

ADULT EQUIVALENT TREATMENT DOSE; ANTIMALARIAL AVAILABILITY; ANTIMALARIAL STOCKING OUTLET; ARTICLE; BLOOD ANALYSIS; CAMBODIA; CASE MANAGEMENT; COMBINATION CHEMOTHERAPY; DRUG DOSE; DRUG INFORMATION; DRUG RETAIL PRICE; DRUG SALES; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HEALTH CARE AVAILABILITY; HEALTH CARE CONCEPTS; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; MALARIA; MALARIA BLOOD TESTING; MEDICAL AUDIT; MONOTHERAPY; PHARMACY; PRIVATE FOR PROFIT HEALTH FACILITY; PUBLIC HEALTH FACILITY; QUESTIONNAIRE; TREND STUDY; VILLAGE MALARIA WORKER; CROSS-SECTIONAL STUDY; HEALTH SERVICES RESEARCH; ORGANIZATION AND MANAGEMENT; POLICY;

ANTIMALARIALS; CAMBODIA; CASE MANAGEMENT; CROSS-SECTIONAL STUDIES; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; MALARIA; PHARMACIES; POLICY;

EID: 84966309370     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1200-2     Document Type: Article

References (33)

1. WHO. World Malaria Report 2014. Geneva: World Health Organization. 2014.
2. CNM. Strategic plan for elimination of malaria in Cambodia 2011-2025 DRAFT. Phnom Penh: Ministry of Health. 2015.
3. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670-9. doi: 10.1093/infdis/jiu491.
4. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209-18.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67. doi: 10.1056/NEJMoa0808859.
6. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851-8. doi: 10.1016/S1473-3099(12)70181-0.
7. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960-6. doi: 10.1016/S0140-6736(12)60484-X.
8. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013;8:e57689. doi: 10.1371/journal.pone.0057689.
9. Noedl H. Artemisinin resistance: how can we find it? Trends Parasitol. 2005;21:404-5. doi: 10.1016/j.pt.2005.06.012.
10. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science. 2004;305:1124. doi: 10.1126/science.1098876.
11. Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg. 1986;89:277-89.
12. WHO. Global report on antimalarial drug efficacy and drug resistance 2000-2010. Geneva: World Health Organization 2010.
13. Lubell Y, Dondorp A, Guerin PJ, Drake T, Meek S, Ashley E, et al. Artemisinin resistance-modelling the potential human and economic costs. Malar J. 2014;13:452. doi: 10.1186/1475-2875-13-452.
14. National Centre for Parasitology EaMCC. Cambodia Malaria Survey 2013.
15. Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM, et al. Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J. 2011;10:328. doi: 10.1186/1475-2875-10-328.
16. Ministry of Health. Malaria elimination action framework 2016-2020. Draft 2015.
17. Sim K. Public private partnership on the fight against malaria powerpoint presentation 2012.
18. Patouillard E, Hanson K, Kleinschmidt I, Palafox B, Tougher S, Pok S, et al. Determinants of price setting decisions on anti-malarial drugs at retail shops in Cambodia. Malar J. 2015;14:224. doi: 10.1186/s12936-015-0737-9.
19. O'Connell KA, Poyer S, Solomon T, Munroe E, Patouillard E, Njogu J, et al. Methods for implementing a medicine outlet survey: lessons from the anti-malarial market. Malar J. 2013;12:52. doi: 10.1186/1475-2875-12-52.
20. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D. The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J. 2011;10:325. doi: 10.1186/1475-2875-10-325.
21. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011;10:326. doi: 10.1186/1475-2875-10-326.
22. WHO. Guidelines for the treatment of malaria. 2nd ed. 2010.
23. Chour CM. Success and challenge of multi sectoral collaboration for malaria control and elimination examples in Cambodia [Powerpoint Presentation]. In press 2013.
24. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health. 2004;9:1241-6. doi: 10.1111/j.1365-3156.2004.01342.x.
25. Yeung S, Van Damme W, Socheat D, White NJ, Mills A. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J. 2008;7:96. doi: 10.1186/1475-2875-7-96.
26. Ubben D, Poll EM. MMV in partnership: the Eurartesim(R) experience. Malar J. 2013;12:211. doi: 10.1186/1475-2875-12-211.
27. Palmer KS, Komatsu R, Low-Beer D, Fatumbi B, Samphornarann T, Thompason, M. Cambodia - Malaria Programme Review. 2012.
28. Montagu D. Large-Scale Malaria Treatment in the Private Sector: a case study of the Cambodian experience. San Francisco: The Global Health Group, Global Health Sciences, San Francisco: University of California. 2010.
29. Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J. 2011;10:243. doi: 10.1186/1475-2875-10-243.
30. Poyer S, Shewchuk T, Tougher S, Ye Y, Mann AG, Willey BA, et al. Availability and price of malaria rapid diagnostic tests in the public and private health sectors in 2011: results from 10 nationally representative cross-sectional retail surveys. Trop Med Int Health. 2015;20:744-56. doi: 10.1111/tmi.12491.
31. WHO. Disease Surveillance for Malaria Elimination: an Operational Manual. Geneva: World Health Organization 2012.
32. Roca-Feltrer A, Ashton R, Nicholas S. Cambodia malaria survey 2013. 2014.
33. Yeung S, Lawford HL, Tabernero P, Nguon C, van Wyk A, Malik N, et al. Quality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia. Am J Trop Med Hyg. 2015;92(6 Suppl):39-50. doi: 10.4269/ajtmh.14-0391.